METABOLOMICA, A TOOL USED IN THE EVALUATION OF BIOLOGICAL SYSTEMS OF VARIABLE COMPLEXITY, HAS ENORMOUS POTENTIAL IN A LARGE NUMBER OF AREAS, INCLUDING THE DISCOVERY AND DEVELOPMENT OF PHARMACOS, EARLY DIAGNOSIS OF DISEASES, MONITORING AND STRATIFICATION OF PATIENTS, AND EVALUATION OF RESPONSE TO TREATMENT. THROUGH DETAILED ANALYSIS OF SMALL MOLECULAR WEIGHT MOLECULES PRESENT IN BIOLOGICAL SAMPLES, METABOLOMICA COULD FACILITATE A BETTER UNDERSTANDING OF PHARMACO ACTIVITY AND THE IDENTIFICATION OF NEW TARGETS. Although the application of the METABOLOMIC in FARMACEUTICA INDUSTRIA is found still in its initial state, this EXPERIMENTAL focus offers the possibility of entering into our knowledge on the mechanism of action of pharmacies through the examination of METABOLICAL journeys, associated TO THE RESPONSE AS TO ADVERSED REACTIONS, INDUCED BY THE MISSMOS._x000D_ METABOLOMIC CAN BE CONSIDERED THE OICICAL MASTER CERRCATE TO THE FENOTYPE. THE METABOLIC SIGNATURE OF A PATIENT, USUALLY OBTAINED NON-INVASIVELY FROM BIOFLUID ANALYSIS, CONTAINS INFORMATION RELATED TO THE GENOTYPE, BUT ALSO TO OTHER FACTORS SUCH AS DISEASE PROGRESSION OR RESPONSE TO TREATMENTS. THIS EXPLAINS WHY METABOLOMICA IS ATTRACTING SO MUCH INTEREST FOR THE IDENTIFICATION OF BIOMARKERS OF DIAGNOSTIC VALUE AND FOR THE FOLLOW-UP OF PATIENTS OF DIFFERENT PATHOLOGIES. IN PARTICULAR, ONCOLOGIC PROCESSES, WHICH INVOLVE THE DEREGULATION OF MULTIPLE BIOCHEMICAL PATHWAYS, ARE EXCELLENT CANDIDATES FOR THE CONDUCT OF METABOLOMIC STUDIES. ALTHOUGH THERE ARE CURRENTLY PHARMACOLOGICAL TREATMENTS WITH PROVEN EFFICACY TO TREAT MANY OF THESE PROCESSES, A SIGNIFICANT PROPORTION OF PATIENTS DO NOT FULLY RESPOND TO THE PHARMACOS AND/OR SUFFER ADVERSE REACTIONS TO THEM. The variability in the pathophysiology of the disease, together with the INDIVIDUAL DIFFERENCES in the answer to the treatment, CONSTITUY THE BASE OF THE ESFUERZS BY PERSONALISING THIS TYPE OF TERAPIAS._x000D_ THE PRINCIPAL OBJECTIVE OF THIS PROJECT IS TO CONTRIBUTE, by means of the analyses of the meta-ABOLOMIC CHARACTERISTIC PROCEDURES of two prevalent oncologic processes (MULTIPLE MELOMA AND CANCER of non-MICROCITIC PULMON), to the development of a platform that allows to anticipate the introduction of this technology in pharmactic and clinical environments. IN THIS SENSE, TECHNIQUES OF METABOLOMICA BY MRI WILL BE USED FOR THE IDENTIFICATION OF NEW TARGETS RELATED TO THE APPEARANCE OF THESE PATHOLOGIES, AS WELL AS FOR THE CHARACTERISATION OF MOLECULAR MECHANISMS INVOLVED IN THE RESPONSE/RESISTANCE TO DIFFERENT TREATMENTS CURRENTLY USED IN THE TREATMENT OF THESE PATHOLOGIES. THIS SAME TYPE OF EXPERIMENTAL APPROACHES ARE ALSO USED TO IDENTIFY BIOMARKERS THAT FACILITATE THE UNDERSTANDING OF PHARMACOLOGICAL ACTIVITY AND SELECTIVITY OF DIFFERENT ANTINEOPLASIC DRUGS, AS WELL AS A MORE RATIONAL WAY TO MONITOR AND GUIDE TREATMENTS BASED ON A BETTER KNOWLEDGE OF THE CHARACTERISTICS OF DIFFERENT SUBPOPULATIONS OF PATIENTS.